Silence Therapeutics Gets 130% Premium Offer From Merck, Shares Surge Over 100%
FROM THE WIRE · FINANCE.YAHOO.COM
Silence Therapeutics (NASDAQ:SLN) kicked off the trading week by more than doubling its share price, as investors snapped up its shares following Merck KGaA's offer to acquire the company for a 130-percent premium. In separate statements on the same day, Merck KGaA and Silence…
Read at the source ↗MARKET IMPACTHIGH✦ News Impact agent estimateTone: expected bullishAll-cash acquisition at a 130% premium that sends the stock up over 100%, relevant for the biotech sector.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Merck KGaA will acquire all Silence Therapeutics ADS at $20 apiece.
- 02The all-cash deal is worth $1.3 billion, subject to regulatory conditions.
- 03The stock closed up 125.58% at $19.58.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Silence Therapeutics plc19.58 USDMarket closedtoday +125.58%Positive Merck KGaA144.35 EURMarket closedtoday +0.03%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets